Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease

被引:15
作者
El-Matary, Wael [1 ,2 ,3 ,5 ]
Abej, Esmail [4 ]
Deora, Vini [1 ,3 ]
Singh, Harminder [2 ,4 ]
Bernstein, Charles N. [2 ,4 ]
机构
[1] Univ Manitoba, Sect Pediat Gastroenterol, Dept Pediat & Child Hlth, Winnipeg, MB, Canada
[2] Univ Manitoba, IBD Clin & Res Ctr, Winnipeg, MB, Canada
[3] Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada
[4] Univ Manitoba, Gastroenterol Sect, Dept Internal Med, Winnipeg, MB, Canada
[5] Univ Alexandria, Alexandria, Egypt
关键词
calprotectin; children; colitis; Crohn; IBD; ULCERATIVE-COLITIS; ACTIVITY INDEX; MARKERS; BLOOD; LACTOFERRIN; VALIDATION; RELAPSE;
D O I
10.3389/fped.2017.00007
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: The use of fecal calprotectin (FCal) as a marker of intestinal inflammation, in the management of inflammatory bowel disease (IBD) is increasing. The aim of this study was to examine the impact of FCal measurements on decision-making and clinical care of children with IBD. Materials and methods: In a retrospective cohort study, FCal, clinical activity indices, and blood markers were measured in children with established diagnoses of IBD. Pearson correlation coefficient analysis was performed to examine association between FCal and other markers. Decisions based on FCal measurements were prospectively documented and participants were evaluated 3-6 months later. Results: A total of 115 fecal samples were collected from 77 children with IBD [median age 14, interquartile range (IQR) 11-15.6 years, 42 females, 37 with Crohn's disease]. FCal positively correlated with clinical activity indices (r = 0.481, P < 0.05) and erythrocyte sedimentation rate (r = 0.40, P < 0.05) and negatively correlated with hemoglobin (r = -0.40, P < 0.05). Sixty four out of 74 (86%) positive FCal measurements (>= 250 mu g/g of stools) resulted in treatment escalation with subsequent significant clinical improvement while in the FCal negative group, 34 out of 41 (83%) measurements resulted in no change in treatment and were associated with remission on follow-up. Conclusion: Based on high FCal, the majority of children had treatment escalation that resulted in clinical improvement. FCal measurements were useful and reliable in decision-making and clinical care of children with IBD.
引用
收藏
页数:7
相关论文
共 27 条
[1]   The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease [J].
Abej, Esmail ;
El-Matary, Wael ;
Singh, Harminder ;
Bernstein, Charles N. .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 2016
[2]   Fecal Markers: Calprotectin and Lactoferrin [J].
Abraham, Bincy P. ;
Kane, Sunanda .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2012, 41 (02) :483-+
[3]   Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review [J].
Alibrahim, Bashaar ;
Aljasser, Mohammed I. ;
Salh, Baljinder .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 29 (03) :157-163
[4]   Challenges in pediatric inflammatory bowel disease [J].
Bousvaros, Athos ;
Sylvester, Francisco ;
Kugathasan, Subra ;
Szigethy, Eva ;
Fiocchi, Claudio ;
Colletti, Richard ;
Otley, Anthony ;
Amre, Devendra ;
Ferry, George ;
Czinn, Steven J. ;
Splawski, Judy B. ;
Oliva-Hemker, Maria ;
Hyams, Jeffrey S. ;
Faubion, William A. ;
Kirschner, Barbara S. ;
Dubinsky, Marla C. .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (09) :885-913
[5]   Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease [J].
Bunn, SK ;
Bisset, WM ;
Main, MJC ;
Golden, BE .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2001, 32 (02) :171-177
[6]   Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease [J].
Canani, R. Berni ;
Terrin, G. ;
Rapacciuolo, L. ;
Miele, E. ;
Siani, M. C. ;
Puzone, C. ;
Cosenza, L. ;
Staiano, A. ;
Troncone, R. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (07) :547-553
[7]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[8]   Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].
D'Haens, Geert ;
Ferrante, Marc ;
Vermeire, Severine ;
Baert, Filip ;
Noman, Maja ;
Moortgat, Liesbeth ;
Geens, Patricia ;
Iwens, Doreen ;
Aerden, Isolde ;
Van Assche, Gert ;
Van Olmen, Gust ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224
[9]   Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis [J].
De Vos, M. ;
Dewit, O. ;
D'Haens, G. ;
Baert, F. ;
Fontaine, F. ;
Vermeire, S. ;
Franchimont, D. ;
Moreels, T. ;
Staessen, D. ;
Terriere, L. ;
Vander Cruyssen, B. ;
Louis, E. .
JOURNAL OF CROHNS & COLITIS, 2012, 6 (05) :557-562
[10]  
Eccles J, 2014, GASTROENTEROLOGY, V146, pS798